Europe 1 with AFP 3:13 p.m., December 16, 2021
The European Medicines Agency (EMA) on Thursday approved two new treatments for Covid-19, the monoclonal antibody treatment of GlaxoSmithKline as well as an immunosuppressive drug already authorized in the EU for the treatment of various inflammatory conditions.
The European Medicines Agency (EMA) on Thursday approved two new treatments for Covid-19, the monoclonal antibody treatment of GlaxoSmithKline as well as an immunosuppressive drug already authorized in the EU for the treatment of various inflammatory conditions.
GSK treatment "is intended for the treatment of Covid-19 in adults and adolescents who do not need supplemental oxygen and who are at increased risk of the severity of the disease," the EMA said in a statement , while the use of Kineret has been "extended to the treatment of Covid-19 in adult patients (...) who need supplemental oxygen (...) and who are at risk of developing severe respiratory failure ".
>> More information to follow ...